Bodine Journal

Article Title

Combination of Vandetanib, Radiotherapy, and Irinotecan in the LoVo Human Colorectal Cancer Xenograft Model

Authors

Phyllis Wachsberger, PhD, Thomas Jefferson UniversityFollow
Randy Burd, PhD, Department of Nutritional Sciences, University of Arizona, Tuscon AZFollow
Anderson Ryan, PhD, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, United KingdomFollow
Constantine Daskalakis, PhD, Thomas Jefferson UniversityFollow
Adam Dicker MD, PhD, Thomas Jefferson UniversityFollow

Abstract

Purpose:

The tumor growth kinetics of the human LoVo colorectal xenograft model was assessed in response to vandetanib, an orally available receptor tyrosine kinase inhibitor, radiotherapy (RT), or irinotecan (CPT-11), as single therapies and in combination.

Methods and Materials:

LoVo cells were injected subcutaneously into the right hind limb (5x106 cells in 100μL phosphate-buffered saline) of athymic NCR NUM mice and tumors were grown to a volume of 200–300mm3 before treatment. Vandetanib was administered at 50 mg/kg daily orally for 14 days starting on Day 1. RT was given as three fractions (3x3 Gy) on Days 1, 2, and 3. CPT-11 was given at 15 mg/kg intraperitoneally on Days 1 and 3. Tumor volumes were measured on a daily basis and calculated by measuring tumor diameters with digital calipers in two orthogonal dimensions.

Results:

All three single treatments (vandetanib, CPT-11, and radiation) significantly slowed LoVo colorectal tumor growth. Vandetanib significantly increased the antitumor effects of CPT-11 and radiation when given in combination with either of these treatments. These treatment combinations resulted in a slow tumor growth rate during the 2 weeks of vandetanib administration. The triple combination of vandetanib, CPT-11, and radiation produced the most marked improvement in response as observed by measurable shrinkage of tumors during the first week of treatment.

Conclusions:

The tumor growth delay kinetics observed in this study of the LoVo colorectal model suggest concurrent and sustained post-sequencing of vandetanib with cytotoxic therapy may be beneficial in tumors of this type.

Reprinted from International Journal of Radiation Oncology*Biology*Physics, Volume 75, Edition 3, Wachsberger P, Burd R, Ryan A, Daskalakis C, Dicker AP: “Combination of Vandetanib, Radiotherapy, and Irinotecan in the LoVo Human Colorectal Cancer Xenograft Model”, pages 843-853, November 1, 2009.

Recommended Citation

Wachsberger, PhD, Phyllis; Burd, PhD, Randy; Ryan, PhD, Anderson; Daskalakis, PhD, Constantine; and Dicker, Adam MD, PhD (2009) "Combination of Vandetanib, Radiotherapy, and Irinotecan in the LoVo Human Colorectal Cancer Xenograft Model," Bodine Journal: Vol. 2: Iss. 1, Article 3.
DOI: https://doi.org/10.29046/TBJ.002.1.002
Available at: https://jdc.jefferson.edu/bodinejournal/vol2/iss1/3